TCGA-E2-A105-01A-11R-A10J-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 44
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.390
- PANCREAS_BETA_CELLS+0.310
- DNA_REPAIR+0.290
- G2M_CHECKPOINT+0.270
- E2F_TARGETS+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.120
- WNT_BETA_CATENIN_SIGNALING+0.110
- MYC_TARGETS_V2+0.090
- ESTROGEN_RESPONSE_LATE+0.080
- SPERMATOGENESIS+0.040
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- INTERFERON_GAMMA_RESPONSE-0.530
- INTERFERON_ALPHA_RESPONSE-0.510
- IL6_JAK_STAT3_SIGNALING-0.500
- ANDROGEN_RESPONSE-0.450
- COMPLEMENT-0.440
- TNFA_SIGNALING_VIA_NFKB-0.430
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797255 | — | cohortSC | 0.921 |
| 2 | TCGA-E2-A15S-01A-11R-A115-07 | — | B | 0.916 |
| 3 | BS_V9HVBBDW | medulloblastoma | — | 0.915 |
| 4 | BS_E3BAT4C1 | medulloblastoma | — | 0.913 |
| 5 | BS_QPPPGYP4 | medulloblastoma | — | 0.912 |
| 6 | BS_Y8D1F5WW | medulloblastoma | — | 0.912 |
| 7 | BS_ERWT0ZWE | medulloblastoma | — | 0.910 |
| 8 | BS_GE2RVZE6 | medulloblastoma | — | 0.909 |
| 9 | BS_G00FHF3Q | medulloblastoma | — | 0.908 |
| 10 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.020 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |